Adam C. Berger, MD, FACS, chief of Melanoma and Soft Tissue Surgical Oncology and associate director for Shared Resources at Rutgers Cancer Institute of New Jersey addresses common questions about sarcoma during sarcoma awareness month.
Researchers in Center of Excellence for Evolutionary Therapy at Moffitt Cancer Center are thinking outside the box and studying an alternative approach called adaptive therapy that is based on evolutionary principles and mathematical modeling. In a new article in eLife, the researchers report updated results from a pilot clinical trial evaluating an adaptive therapy approach using the drug abiraterone to treat patients with metastatic castrate-resistant prostate cancer.
Researchers at Washington University School of Medicine in St. Louis are leading a national study aimed at identifying patients with early-stage lung cancer who are at high risk of having the cancer return, even after surgery and chemotherapy appear to have eliminated their tumors. The research is supported by a $5.3 million grant from the National Cancer Institute of the National Institutes of Health (NIH).
Building on Penn Medicine’s years of research and use of imaging technology that illuminates tumor tissue—helping clinicians more easily detect and remove it—the Perelman School of Medicine at the University of Pennsylvania has received a five-year, $9 million research grant from the National Cancer Institute (NCI) to push the field forward, particularly for lung cancer patients.
Scientists at St. Jude Children’s Research Hospital identified proteins that help decide T cell fate and used the finding to improve CAR-T cell therapy in a solid tumor model.
Researchers at Case Western Reserve University and the University of Washington expect to gain valuable new insights into highly aggressive prostate cancer by combining Artificial Intelligence (AI)-powered diagnostic imaging with three-dimensional (3D) tissue imaging.
A collaborative study from UT Southwestern scientists has identified a new function for a protein called TAO2 that appears to be key to inhibiting replication of the influenza virus, which sickens millions of individuals worldwide each year and kills hundreds of thousands. The findings were published in PNAS.
A world-class team of researchers assembled and led by Rutgers Cancer Institute of New Jersey and its Deputy Director and Chief Scientific Officer Eileen White, PhD, has been awarded a $25 million Cancer Grand Challenges grant to tackle the condition of cancer cachexia.
A team of researchers at the University of Michigan Rogel Cancer Center were the first to generate a bona fide mouse model of a Merkel cell carcinoma, a rare and potentially aggressive form of skin cancer. The study outlining these results appeared in the Journal of Clinical Investigation.
A new study by researchers at Washington University School of Medicine in St. Louis shows that treatment with an immunity boosting protein called interleukin 7 (IL-7) after an infusion of genetically modified T cells causes the cancer-fighting CAR-T cells to grow in number and become more effective at killing tumor cells.
The University of Chicago Medicine hopes to recruit 50,000 people to participate in a new national study designed to explore the causes of cancer and learn more about how to prevent it.
Rampant inflammation has long been linked to cancer but exactly how it pushes healthy cells to transform into malignant ones has remained a mystery. Now, scientists at Van Andel Institute have found one culprit behind this connection.
A new study, led by researchers from the University of California, Irvine, reveals the unique cell-to-cell communication networks that can perpetuate inflammation and prevent repigmentation in patients with vitiligo disease.
Researchers at UT Southwestern have developed a first-of-its-kind ultrasound-guided cancer immunotherapy platform that delivers immune-stimulating agents to cells for the development of systemic anti-tumor immunity. The technology, termed Microbubble-assisted Ultrasound-guided Immunotherapy of Cancer (MUSIC), was described in a study published in Nature Nanotechnology.
A small molecule discovered and developed by a team of scientists led by Fengzhi Li, PhD, Associate Professor of Oncology in the Department of Pharmacology and Therapeutics at Roswell Park Comprehensive Cancer Center, eliminates human pancreatic and colorectal tumor cells by binding to and degrading DDX5, a powerful cancer-causing protein.
Researchers at the University of Michigan Rogel Cancer Center have found a cell nuclear receptor activated by high fat diets and synthetic substances in unregulated athletic performance enhancers fuels the progression of precancerous pancreas lesions into pancreatic cancer.
In a small but rigorous pilot study, Johns Hopkins Medicine researchers have shown that a novel, minimally invasive biomarker-based strategy they developed was 90% successful in detecting esophageal squamous cell carcinoma (ESCC), the predominant subtype of esophageal cancer worldwide.
In a new study featured on the cover of the May 1 issue of the journal Cancer Research, Moffitt Cancer Center researchers report on their identification of biomarkers based on a type of genetic modification called methylation that predicts the type of tumor immune environment and patient outcomes.
Immunotherapy has transformed treatment for patients with stage 4 metastatic esophageal and gastric cancers. In patients with these malignancies, immunotherapy has been shown to prolong survival when patients' tumors exhibit a high expression of an immune-related protein called PD-L1.
Researchers at Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis have found a way to help more patients who want to stop smoking. The successful strategy involves using electronic medical records to help identify smokers when they visit their oncologists and offering help with quitting during such visits.
Researchers at The University of Texas MD Anderson Cancer Center have identified a novel strategy to reduce immune-related adverse events from immunotherapy treatment by targeting the cytokine interleukin-6 (IL-6).
In a new study published in Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research, Moffitt Cancer Center researchers share the identification of a new potential target for CAR T cells called OR2H1 that they have demonstrated inhibits growth in lung and ovarian tumors
The Association of American Cancer Institutes (AACI) welcomes its newest member, the Koch Institute for Integrative Cancer Research at MIT.
Researchers at the Case Western Reserve University School Medicine have found that combining two cancer drugs can be effective in treating a specific type of colorectal cancer, according to a new study published in Nature Communications.
Johns Hopkins biomedical engineers have developed an artificial intelligence (AI) training strategy to capture images of mouse brain cells in action. The researchers say the AI system, in concert with specialized ultra-small microscopes, make it possible to find precisely where and when cells are activated during movement, learning and memory.
Moffitt Cancer Center researchers are working to improve the ability to identify patients who are at a higher risk of poor survival through radiomics, an area of science that uses imaging, such as CT scans and MRIs, to uncover tumoral patterns and characteristics that may not be easy to spot by the naked eye. Results of their newest study was published today in Cancer Biomarkers.
Bladder cancer affects nearly 84,000 people in the United States each year, making it the sixth most common cancer. Most people survive it, but unfortunately, many lose their bladders. Neda Hashemi, MD, and her team at The University of New Mexico Comprehensive Cancer Center are now offering several clinical trials, including one that will give people with bladder cancer a chance to fight their disease and keep their bladders.
Zakrzewski Lab aims to train immune system to make its own CAR T cells
Researchers have developed a new computational tool to select optimal combination therapies for patients with cancer based on the co-occurring alterations in a given tumor.
Moffitt Cancer Center researchers have revealed that the creation of an immunosuppressive environment is key to the progression of benign colorectal adenomas to invasive, malignant carcinomas. Their findings were published in Nature Communications.
Mutation of a gene called ARID2 plays a role in increasing the chance that melanoma, a deadly skin cancer, will turn dangerously metastatic, Mount Sinai researchers report.
A simple blood test for women of all ages and risk levels could one day be possible thanks to a new set of protein biomarkers that researchers identified using breast milk.
Cancer of the appendix is rare, affecting only 1 in 100,000 people in the United States annually. However, because it’s so rare, there’s limited research to help guide treatment decisions. But now, researchers at Atrium Health Wake Forest Baptist’s NCI-designated Comprehensive Cancer Center hope to change that with support from a $2.5 million grant from the National Cancer Institute.
Researchers discovered that two distinct classes of fibroblast cells accumulate in pancreatic tumors and play opposing roles to promote and restrain pancreatic cancer growth. Appropriately targeting these cells may offer options to improve treatment outcomes.
NIBIB-funded researchers are developing a method to activate natural killer cells using an external magnetic field, which not only enhances their cytotoxicity, but allows them to be tracked using magnetic resonance imaging (MRI) to verify that they’ve reached their target.
Adding an anti-inflammatory medication to immunotherapy and standard chemotherapy drugs may provide long-term suppression of aggressive bladder tumor growth, according to a proof-of-concept study led by Cedars-Sinai Cancer investigators.
Consumer interest and awareness in nicotine pouches – products that contain nicotine but have no tobacco and one of the newest industry products — is growing and they are most popular among younger smokers and those trying to quit, according to a Rutgers research study.
Hepatitis screening rates climbed to 80 percent for patients whose doctors didn’t need to opt in to order a screening
UChicago researchers discovered several important mechanisms that affect how ovarian cancer tumors interact with the immune response and how combination therapies can exploit these pathways to improve ovarian cancer treatment.
Blocking the protein UBE2N with novel small molecule kills AML cells, according to study in Science Translational Medicine.
.jpeg&width=400&height=400)
With the aid of a recently awarded $3.5 million, five-year National Cancer Institute grant (R01CA262265), Rutgers Cancer Institute of New Jersey, New Jersey’s only NCI-designated Comprehensive Cancer Center, and Tufts Medical Center in Boston are collaborating on groundbreaking work that is unifying global multi-source big data in order to enhance clinical decision support for improved acute and long-term outcomes for Hodgkin lymphoma patients around the world.
The National Cancer Institute recently awarded Yale Cancer Center and Yale School of Public Health a new U01 cooperative agreement grant to support research into the impact of diet and exercise for women with ovarian cancer.
In a new article published in the March issue of Emerging Infectious Diseases, Moffitt researchers set out to estimate the percentage of Hillsborough County residents who had COVID infection and better understand demographics and behavioral factors associated with infection.
Researchers from Moffitt Cancer Center’s Donald A. Adam Melanoma and Skin Cancer Center of Excellence reveal key differences in the cellular and molecular composition of acral melanoma compared to melanoma. Their findings may lead to new potential therapeutic targets for this rare disease.
A Sylvester Comprehensive Cancer Center researcher has been awarded a $5 million seven-year grant from the National Cancer Institute (NCI) to study how advanced imaging during treatment may be used to improve radiation therapy for patients with glioblastoma, a deadly brain tumor.
A team of Moffitt researchers has been able to add an important resource to study leptomeningeal disease by successfully growing and culturing circulating tumor cells derived from the cerebrospinal fluid of patients with melanoma leptomeningeal disease.
The Center for Tobacco Studies at Rutgers, The State University of New Jersey received a $2.6 million grant from the National Cancer Institute (NCI) to evaluate cigarette relighting – the practice of smoking a cigarette, extinguishing it, and lighting it again to smoke – as well as its consequences on health and efforts to quit smoking.
The incidence of cervical cancer is starting to rise in low-income U.S. counties and has plateaued in high-income counties in recent years, after years of decreases, according to a new study led by investigators from The University of Texas Health Science Center at Houston (UTHealth Houston) and published in JNCI Cancer Spectrum.
Johns Hopkins Medicine researchers have developed and tested a new imaging approach they say will accelerate imaging-based research in the lab by allowing investigators to capture images of blood vessels at different spatial scales.
A Stony Brook University physician-scientist has identified that mucosal-associated invariant T (MAIT) cells exercise several complex roles during healthy and disease states. The published findings may help to serve as a benchmark for future research on MAIT cells as targets for immunotherapies and vaccines.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
